Jenna Sinopoli

Clinical Trials Nurse Practitioner at MSKCC

[Jenna Sinopoli @JennaSinopoli]

So proud to be apart of this team! ⭐️

[Mike Foote @MikeFooteMD]

All smiles from the @AndreaCercek research team after her ground-breaking presentation. “This has never happened in the history of cancer” from @nytimes https://t.co/XyloeP4IKS

[Boundless Bio @BoundlessBio]

Check out our new publication with @MSKCancerCenter demonstrating #ecDNA - based KRAS G12C amplification as a recurrent resistance mechanism to KRASG12Ci + EGFRi treatment in CRC! https://t.co/6Ntpfug8bN @KRASkickers #oncology

[CBS Mornings @CBSMornings]

A recent @MSKCancerCenter trial had an unprecedented success rate — and it could have dramatic implications for other cancers: “The tumor’s completely gone.”

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

🚨 Breaking #ASCO22 News: Breakthrough findings published in @NEJM by MSK experts @AndreaCercek & Luis Diaz show 100% complete response rate in all patients who received #immunotherapy treatment for mismatch repair deficient locally advanced #RectalCancer. https://t.co/xlUfR9CKQz

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

@dralanburguete @AndreaCercek Hear from four patients who participated in the clinical trial and how it changed their lives. #ASCO22 @ASCO @NEJM @AndreCercek

[Andrea Cercek @AndreaCercek]

Very proud of our study published in @NEJM. 100% clinical complete response with dostarlimab alone in mismatch repair-deficient locally advanced #RectalCancer. No radiation or surgery! @ASCO #ASCO22 @MSKCancerCenter https://t.co/sZypoHBtj7

[Mike Foote @MikeFooteMD]

All smiles from the @AndreaCercek research team after her ground-breaking presentation. “This has never happened in the history of cancer” from @nytimes https://t.co/XyloeP4IKS

[Dr Joseph McCollom DO @realbowtiedoc]

Dr Luis Diaz of @MSKCancerCenter discusses the challenges of how MSS tumors don't respond to ✅ point inhibitors, low TMB and low PDL1 and peritumoral inflammation #crcsm #GIonc #ASCO22

[Gideon Gil @GideonGil]

Exciting results out of #ASCO22: The @MSKCancerCenter doctors decided to change the study so that patients would not require radiation, chemotherapy, or surgery. Just six months of immunotherapy treatment was enough by itself. https://t.co/fC57FbjgYy via @statnews

[Naedine Hazell @njoyhazell]

via ⁦@nytimes Small trial, Big Results https://t.co/O6I6XLZysb

[Tiago Biachi @BiachiTiago]

Unbelievable data presented by @AndreaCercek with 100% CR for MSI rectal cancer with dostarlimab. No surgery, no chemo, no radiation and NO CANCER! Congrats you all! @AndreaCercek @LumishMelissa, Luiz Diaz and @MSKCancerCenter team! @OncoAlert #asco22

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

With the right molecular signal, a cancer drug works in every patient https://t.co/BF6R51Gfcc via @statnews @AndreaCercek #ASCO22

[Erika Ruiz-Garcia, MD, FASCO @Betzabe100]

Impressive work, congratulations to Dr. @AndreaCercek and her team! @MSKCancerCenter this is Practice Changing 👏🏻👏🏻 #ASCO2022 @OncoAlert

[Eric Topol @EricTopol]

'A complete remission in every single patient is “unheard-of”'
Combining genomics diagnosis of mismatch repair deficient + PD-1 immunotherapy led to complete remission of 18 consecutive patients w/ advanced colorectal cancer https://t.co/54yFGoTDoZ
https://t.co/CZsoFHM0Gl #ASCO22

[Melissa Lumish MD @LumishMelissa]

Now published in @NEJM we describe 100% clinical CR with dostarlimab alone in 12 patients with locally advanced dMMR rectal cancer!Our team leader @AndreaCercek @MSKCancerCenter presenting the data @ASCO #ASCO22

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

@SU2Cscience @SU2C Hear from four patients who participated in the clinical trial and how it changed their lives. #ASCO22 @ASCO @NEJM @AndreCercek

[NYT Health @NYTHealth]

“I believe this is the first time this has happened in the history of cancer,” Dr. Diaz said. Still, the trial will need to be replicated in other patients. https://t.co/EKxUnqpFN9

[Alan Burguete-Torres M.D. @dralanburguete]

Well deserved ovation to Dr. @AndreaCercek and the GI Onc team at @MSKCancerCenter . Yes, you’re reading well: 100% cCCR in pts w/ MSI-H / dMMR LA Rectal Cancer w/ IO. This means possibly no need for CT, RT or Surgery! This is a game changer for our patients!